Weight-loss Drug Response Varies, But Why?

Study links DNA variants to weight loss and side effects

May 5, 2026
2 min

The Pathologist

Share

A recent study published in Nature highlights the role of common genetic variations in predicting patient responses to GLP-1-based weight-loss medications like semaglutide and tirzepatide. Analyzing data from nearly 28,000 participants, researchers found that variations in the GLP1 receptor gene correlated with weight loss, with each variant linked to an average additional loss of approximately 0.76 kg. The findings suggest that genetics, alongside clinical factors such as sex and treatment duration, play a significant role in treatment response and side effects, supporting a more personalized approach to weight management therapies.

Original Source(s)

The Pathologist

Weight-loss Drug Response Varies, But Why?

May 5, 2026

Related Content

The Medicine Maker

This Week’s CGT News: CRISPR Hits Phase 3 Milestone

Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal

May 4, 2026
7 min

The Ophthalmologist

Bridging the Diabetic Eye Care Divide

Study evaluates eye care utilization of diabetic patients in Northern Uganda, spotlighting limited health literacy and awareness as determining factors in care

May 1, 2026
3 min

The Medicine Maker

This Week’s Biopharma News: Wave of Antibody Approvals

FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars

April 28, 2026
5 min